Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

OBJECTIVE: Crizotinib can target against mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK), which has been considered as a multi-targeted tyrosine kinase inhibitor (TKI). The objective of this study was to explore the efficacy of crizotinib in advanced non-small-cell lung...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:BMC Cancer
Main Authors: Chen, Rui-Lian, Zhao, Jun, Zhang, Xu-Chao, Lou, Na-Na, Chen, Hua-Jun, Yang, Xue, Su, Jian, Xie, Zhi, Zhou, Qing, Tu, Hai-Yan, Zhong, Wen-Zhao, Yan, Hong-Hong, Guo, Wei-Bang, Wu, Yi-Long, Yang, Jin-Ji
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2018
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6258481/
https://ncbi.nlm.nih.gov/pubmed/30477470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-5078-y
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker